HUP0201629A2 - Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása - Google Patents
Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazásaInfo
- Publication number
- HUP0201629A2 HUP0201629A2 HU0201629A HUP0201629A HUP0201629A2 HU P0201629 A2 HUP0201629 A2 HU P0201629A2 HU 0201629 A HU0201629 A HU 0201629A HU P0201629 A HUP0201629 A HU P0201629A HU P0201629 A2 HUP0201629 A2 HU P0201629A2
- Authority
- HU
- Hungary
- Prior art keywords
- eletriptan
- pharmaceutical
- cyclodextrin
- derivative
- preparation
- Prior art date
Links
- OTLDLQZJRFYOJR-LJQANCHMSA-N eletriptan Chemical compound CN1CCC[C@@H]1CC1=CN=C2[C]1C=C(CCS(=O)(=O)C=1C=CC=CC=1)C=C2 OTLDLQZJRFYOJR-LJQANCHMSA-N 0.000 title abstract 2
- 229960002472 eletriptan Drugs 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nanotechnology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Otolaryngology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
A találmány az eletriptán és egy (I) általános képletűciklodextrinszármazék vagy gyógyászatilag elfogadható sójánakkomplexére vonatkozik, ahol a képletben R1a-g, R2a-g és R3a-gjelentése egyaránt -OH vagy -O(CH2)4SO3H csoport; azzal a megkötéssel,hogy az R1a-g csoportok legalább egyikének a jelentése -O(CH2)4SO3Hcsoport. A találmány felöleli továbbá a fenti komplexeket tartalmazó,előnyösen intranazálisan, inhalálás formájában vagy parenterálisanadagolható gyógyászati készítményeket is, melyek olyan betegségekkezelésére használhatók, amelyeknél egy 5HT1B/1D receptor agonistaalkalmazása ajánlott. Ó
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9915231.6A GB9915231D0 (en) | 1999-06-29 | 1999-06-29 | Pharmaceutical complex |
| PCT/IB2000/000746 WO2001000243A1 (en) | 1999-06-29 | 2000-06-02 | Pharmaceutical complex |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP0201629A2 true HUP0201629A2 (hu) | 2003-03-28 |
| HUP0201629A3 HUP0201629A3 (en) | 2003-11-28 |
Family
ID=10856302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU0201629A HUP0201629A3 (en) | 1999-06-29 | 2000-06-02 | Pharmaceutical complex containing eletriptan and cyclodextrin-derivative, pharmaceutical composition containing it, process for its preparation and its use |
Country Status (44)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
| AU2003269965B2 (en) * | 2002-08-20 | 2008-02-21 | Otsuka Pharmaceutical Co., Ltd | Aripiprazole complex formulation and method |
| GB0329918D0 (en) * | 2003-12-24 | 2004-01-28 | West Pharm Serv Drug Res Ltd | Intranasal compositions |
| CN1296391C (zh) * | 2004-03-04 | 2007-01-24 | 中国人民解放军第二军医大学 | 氟代羧烷基环糊精醚类化合物及其制备方法和应用 |
| GB0613925D0 (en) | 2006-07-13 | 2006-08-23 | Unilever Plc | Improvements relating to nanodispersions |
| CN101957330B (zh) * | 2010-06-12 | 2013-10-09 | 南京巨环医药科技开发有限公司 | 磺丁基倍他环糊精含量的测定方法 |
| WO2017122161A1 (en) * | 2016-01-15 | 2017-07-20 | Cadila Healthcare Limited | An intranasal composition comprising 5ht1b/1d receptor agonists |
| US20190224171A1 (en) * | 2018-01-22 | 2019-07-25 | Insys Development Company, Inc. | Liquid rizatriptan compositions |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0166088B1 (ko) * | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5376645A (en) * | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| HU210921B (en) | 1990-03-28 | 1995-09-28 | Chinoin Gyogyszer Es Vegyeszet | Process for preparing inclusion complexes of n-ethoxycarbonyl-3-morpholino-sydnonimine formed with cyclodextrines and pharmaceutical compositions containing them |
| HU211648A9 (en) | 1990-03-28 | 1995-12-28 | Chinoin Gyogyszer Es Vegyeszet | Inclusion complexes of 3-morpholino-sydnonimine or its salts or its tautomer isomer, process for the preparation thereof, and pharmaceutical compositions containing the same |
| BR9106978A (pt) | 1990-10-15 | 1993-09-28 | Pfizer | Derivados de indol |
| ZA941544B (en) | 1993-03-05 | 1994-10-31 | Hexal Pharma Gmbh | Crystalline cyclodextrin complexes of ranitidine hydrochloride, process for their preparation and pharmaceutical compositions containing the same. |
| EP0699079B1 (en) | 1994-03-07 | 2004-09-29 | The Dow Chemical Company | Bioactive and/or targeted dendrimer conjugates comprising genetic materials |
| GB9417310D0 (en) | 1994-08-27 | 1994-10-19 | Pfizer Ltd | Therapeutic agents |
| BR9710289A (pt) | 1996-07-11 | 1999-08-17 | Farmarc Nederland Bv | Composi-Æo farmac-utica contendo sal cido de adi-Æo de medicamento b sico |
| US5998462A (en) | 1996-12-16 | 1999-12-07 | Allelix Biopharmaceuticals Inc. | 5-alkyl indole compounds |
| GB9704498D0 (en) | 1997-03-05 | 1997-04-23 | Glaxo Wellcome Spa | Chemical compound |
| ES2163291T3 (es) | 1997-07-03 | 2002-01-16 | Pfizer | Composiciones farmaceuticas que contienen eletriptan hemisulfato y cafeina. |
| GB9816556D0 (en) * | 1998-07-30 | 1998-09-30 | Pfizer Ltd | Therapy |
| GB9915231D0 (en) * | 1999-06-29 | 1999-09-01 | Pfizer Ltd | Pharmaceutical complex |
-
1999
- 1999-06-29 GB GBGB9915231.6A patent/GB9915231D0/en not_active Ceased
-
2000
- 2000-05-26 CO CO00039185A patent/CO5170494A1/es not_active Application Discontinuation
- 2000-06-02 EP EP00929741A patent/EP1189640B1/en not_active Expired - Lifetime
- 2000-06-02 TR TR2001/03827T patent/TR200103827T2/xx unknown
- 2000-06-02 OA OA1200100328A patent/OA11964A/en unknown
- 2000-06-02 CN CNB008097127A patent/CN1198654C/zh not_active Expired - Fee Related
- 2000-06-02 KR KR1020017016844A patent/KR20020015067A/ko not_active Application Discontinuation
- 2000-06-02 BR BR0011845-1A patent/BR0011845A/pt not_active Application Discontinuation
- 2000-06-02 PL PL00352902A patent/PL352902A1/xx not_active Application Discontinuation
- 2000-06-02 DZ DZ013320A patent/DZ3320A1/fr active
- 2000-06-02 HU HU0201629A patent/HUP0201629A3/hu unknown
- 2000-06-02 ES ES00929741T patent/ES2235879T3/es not_active Expired - Lifetime
- 2000-06-02 YU YU87501A patent/YU87501A/sh unknown
- 2000-06-02 MX MXPA01013274A patent/MXPA01013274A/es active IP Right Grant
- 2000-06-02 AT AT00929741T patent/ATE290884T1/de not_active IP Right Cessation
- 2000-06-02 EE EEP200100697A patent/EE200100697A/xx unknown
- 2000-06-02 JP JP2001505950A patent/JP4454900B2/ja not_active Expired - Fee Related
- 2000-06-02 DE DE60018744T patent/DE60018744T2/de not_active Expired - Lifetime
- 2000-06-02 SK SK1893-2001A patent/SK18932001A3/sk unknown
- 2000-06-02 IL IL14634100A patent/IL146341A0/xx unknown
- 2000-06-02 AU AU47741/00A patent/AU770169B2/en not_active Ceased
- 2000-06-02 NZ NZ515235A patent/NZ515235A/en unknown
- 2000-06-02 UA UA2001129200A patent/UA66932C2/xx unknown
- 2000-06-02 CA CA002376847A patent/CA2376847C/en not_active Expired - Fee Related
- 2000-06-02 CZ CZ20014572A patent/CZ20014572A3/cs unknown
- 2000-06-02 EA EA200101106A patent/EA003908B1/ru not_active IP Right Cessation
- 2000-06-02 WO PCT/IB2000/000746 patent/WO2001000243A1/en active IP Right Grant
- 2000-06-02 GE GE4655A patent/GEP20043377B/en unknown
- 2000-06-02 AP APAP/P/2001/002369A patent/AP2001002369A0/en unknown
- 2000-06-06 PA PA20008496801A patent/PA8496801A1/es unknown
- 2000-06-22 GT GT200000102A patent/GT200000102A/es unknown
- 2000-06-27 UY UY26224A patent/UY26224A1/es not_active Application Discontinuation
- 2000-06-27 PE PE2000000648A patent/PE20010346A1/es not_active Application Discontinuation
- 2000-06-27 AR ARP000103223A patent/AR033337A1/es unknown
- 2000-06-28 TN TNTNSN00142A patent/TNSN00142A1/fr unknown
- 2000-06-28 SV SV2000000112A patent/SV2002000112A/es unknown
- 2000-06-29 EC EC2000003551A patent/ECSP003551A/es unknown
- 2000-06-29 US US09/606,508 patent/US6713461B1/en not_active Expired - Fee Related
-
2001
- 2001-11-16 IS IS6163A patent/IS6163A/is unknown
- 2001-11-26 BG BG106151A patent/BG106151A/xx unknown
- 2001-12-20 ZA ZA200110454A patent/ZA200110454B/xx unknown
- 2001-12-21 HR HR20010951A patent/HRP20010951A2/xx not_active Application Discontinuation
- 2001-12-24 MA MA26450A patent/MA26801A1/fr unknown
- 2001-12-28 NO NO20016430A patent/NO20016430L/no not_active Application Discontinuation
-
2004
- 2004-03-30 US US10/812,440 patent/US20040186076A1/en not_active Abandoned
-
2006
- 2006-04-13 JP JP2006111074A patent/JP2006257091A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP0000299A1 (hu) | Késleltetett hatóanyag-leadású gyógyszerkészítmények | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| FR2727016B1 (fr) | Compositions pharmaceutiques a base d'ondansetron | |
| HUP0003386A2 (hu) | CRF antagonisták alkalmazása depresszió, kardiovaszkuláris betegségek kezelésére szolgáló gyógyszerkészítmények előállítására | |
| HUP0301868A2 (hu) | Gyógyászati készítmény, ami VIIa és XIII-as faktort tartalmaz | |
| HUP0203728A2 (hu) | Formoterolt tartalmazó aeroszolkészítmény | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| MXPA03010402A (es) | Derivados de 4-amino-5-fenil-7-ciclobutil-pirrolo (2,3-d) pirimidina. | |
| DE60032749D1 (de) | Stabilisierte pharmazeutische zusammensetzung enthaltend einen nichtsteroiden entzündungshemmenden wirkstoff und prostaglandin | |
| MY130619A (en) | Pharmaceutical formulations of 5,7,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene | |
| HUT60630A (en) | Process or producing peroral pharmaceutical compositions suitable for treating internal diseases of inflammatory nature | |
| BG105173A (en) | Novel salt form of pantoprazole | |
| MY111260A (en) | Pharmaceutical composition for the treatment of nicotine dependence | |
| ATE298324T1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| HUP0105364A2 (hu) | Spontán diszpergálódó N-benzoil sztaurosporint tartalmazó gyógyszerkészítmények és alkalmazásuk | |
| EE04606B1 (et) | H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks | |
| HUP0400553A2 (hu) | Gyógyászati készítmények | |
| DE602004009552D1 (de) | Orales abgabesystem mit einem antibakteriellen und einem entzündungshemmenden mittel | |
| HUP9901360A2 (hu) | Cimicifuga racemosa-ból származó extraktum alkalmazása | |
| HUP0204511A2 (en) | Use of ppar activator or ligand in preparation of pharmaceutical compositions for treatment of bone diseas | |
| HUP0201629A2 (hu) | Eletriptánt és ciklodextrinszármazékot tartalmazó gyógyászati komplex, ezt tartalmazó gyógyszerkészítmény, eljárás az előállítására és alkalmazása | |
| BRPI0412430A (pt) | polipeptìdeo agonista do receptor de zot e zonulina | |
| BR0212249A (pt) | Composto, composição farmacêutica, método de tratamento ou profilaxia de doenças, e, uso de um composto | |
| HUP0204324A2 (en) | Use of fsh for preparation of pharmaceutical composition suitable for treating infertility | |
| EP1778209B8 (en) | Methods and compositions for oral delivery of fts |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FD9A | Lapse of provisional protection due to non-payment of fees |